<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580381</url>
  </required_header>
  <id_info>
    <org_study_id>FRA-TYS-19-11504</org_study_id>
    <nct_id>NCT04580381</nct_id>
  </id_info>
  <brief_title>Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort</brief_title>
  <acronym>RELEVANT</acronym>
  <official_title>Real World Effectiveness of Natalizumab Extended Interval Dosing in Relapsing-Remitting Multiple Sclerosis in a French Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Natalizumab (NTZ) use in Multiple Sclerosis (MS) in highly active patients has been largely&#xD;
      established during the last Rationale 10 years in both clinical trials and real-world&#xD;
      practice. Along with its efficacy, NTZ use has been limited by potential risk of progressive&#xD;
      multifocal leukoencephalopathy (PML). Thus, several studies have tried to assess how to&#xD;
      minimize this risk.&#xD;
&#xD;
      One suggested approach is to move from the standard interval dose (SID) of 4 weeks to an&#xD;
      extended interval dose (EID) of 5 weeks or longer. Extending the dosing interval of NTZ has&#xD;
      been practiced by some physicians with the intention of improving the benefit/risk of the&#xD;
      treatment by reducing the exposure-dependent risk of progressive multifocal&#xD;
      leukoencephalopathy (PML) while maintaining efficacy. We propose to retrospectively analyze&#xD;
      data from clinical records coming from RRMS patients treated in France at 5 different&#xD;
      centers; Caen, Nice, Bobigny and Toulouse hospitals as well as Percy Military Hospital, to&#xD;
      evaluate the effectiveness of natalizumab EID in subjects who have previously been treated&#xD;
      with natalizumab SID for 12 months, in relation to continued SID treatment. In the clinical&#xD;
      practice of these centers, patients are shifted after minimum 12 months under SID to an EID&#xD;
      of 6 weeks regardless antibody JC serum status. Clinical, magnetic resonance imaging (MRI)&#xD;
      and serum anti-JCV antibody status data are collected when available.&#xD;
&#xD;
      The objective of this study is to assess the efficacy in term of ARR and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Ratio</measure>
    <time_frame>baseline to 12 month follow-up</time_frame>
    <description>relapse rate per patient per year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability progression</measure>
    <time_frame>baseline to 12 month follow-up</time_frame>
    <description>Increase in EDSS score during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEDA-3 achievement</measure>
    <time_frame>baseline to 12 month follow-up</time_frame>
    <description>Estimation of the proportion of patients achieving NEDA-3 criteria at the end of the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological activity</measure>
    <time_frame>baseline to 12 month follow-up</time_frame>
    <description>Detection of increase MRI activity defined as new or enlarged T2 lesions and/or new gadolinium enhancing lesions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety outcome</measure>
    <time_frame>baseline to 12 month follow-up</time_frame>
    <description>Description of PML cases and variations in anti-JCV antibody status when available</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Standard Interval Dosing (SID)</arm_group_label>
    <description>Patients continuing Natalizumab treatment with standard interval dosing defined as &gt; 11 infusions per year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Interval Dosing (EID)</arm_group_label>
    <description>Patients switching to extended interval dosing defined as ≤ 10 infusions per year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natalizumab Injection [Tysabri]</intervention_name>
    <description>Natalizumab infusion interval according to local practice defining the patient's group</description>
    <arm_group_label>Extended Interval Dosing (EID)</arm_group_label>
    <arm_group_label>Standard Interval Dosing (SID)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving Natalizumab as disease-modifying monotherapy for RRMS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving at least 11 infusions of natalizumab as disease-modifying&#xD;
             monotherapy for RRMS that is consistent with the approved dosing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom the NTZ infusion history and/or MRI and clinical history is not&#xD;
             available.&#xD;
&#xD;
          -  Patients with dosing gap defined as &gt;=12 weeks between any two doses.&#xD;
&#xD;
          -  Patients with over dose defined as &lt;3 weeks between any two doses.&#xD;
&#xD;
          -  Pregnancy during the follow-up period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilles DEFER, MD</last_name>
    <phone>33(0)-2-31065490</phone>
    <email>defer-gi@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, CHU Bobigny-Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irène COMAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Percy Military Hospital</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien RICARD, MD</last_name>
      <email>damien.ricard@m4x.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine LEBRUN-FRENAY, MD</last_name>
      <email>lebrun-frenay.c@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, CHU Toulouse Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan CIRON, MD</last_name>
      <email>ciron.j@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Natalizumab</keyword>
  <keyword>Extended Interval Dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

